U.S. biosimilars held back by more than just reimbursement

Policy failures and misaligned incentives have created a $156 billion “biosimilar void” that must be addressed to ensure the sustainability of the biosimilars market and to realize the cost savings that biosimilars can bring, according to a new report from Iqvia. Savings from biosimilars create headroom for higher-priced novel products.

At a time when Congress and the White House are looking for ways to increase competition in the pharma industry, recommendations on how to reduce the cost of biosimilars development are especially timely...